Showing results (271-280 of 398) with videos related to

Sort By:
Pageof 40
Behavioural Brain Research|June 19, 2016
Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive functionLay Khoon Too, Kong M Li, Cacang Suarna, et al.
Brain Research Bulletin|February 16, 2016
Contrasting regional Fos expression in adolescent and young adult rats following acute administration of the antidepressant paroxetineEmily A Karanges, Linnet Ramos, Bruno Dampney, et al.
The International Journal on Drug Policy|September 12, 2020
Access to cannabidiol without a prescription: A cross-country comparison and analysisIain S McGregor, Elizabeth A Cairns, Sarah Abelev, et al.
Psychopharmacology|March 19, 2004
MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the ratKelly J Clemens, Petra S Van Nieuwenhuyzen, Kong M Li, et al.
Drug Testing and Analysis|August 24, 2019
Detection of Δ9 THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devicesThomas R Arkell, Richard C Kevin, Jordyn Stuart, et al.
Journal of Cannabis Research|January 4, 2022
Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndromeLyndsey L Anderson, Michael Udoh, Declan Everett-Morgan, et al.
Harm Reduction Journal|June 10, 2020
Medical cannabis use in the Australian community following introduction of legal access: the 2018-2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18)Nicholas Lintzeris, Llewellyn Mills, Anastasia Suraev, et al.
Iscience|August 30, 2022
Sex-specific transcriptomic and epitranscriptomic signatures of PTSD-like fear acquisitionAndre L M Reis, Jillian M Hammond, Igor Stevanovski, et al.
Harm Reduction Journal|May 28, 2024
Medical cannabis use in Australia seven years after legalisation: findings from the online Cannabis as Medicine Survey 2022-2023 (CAMS-22)Llewellyn Mills, Jonathon C Arnold, Anastasia Suraev, et al.
Frontiers in Pharmacology|June 14, 2019
CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor AgonistRichard C Kevin, Lyndsey Anderson, Iain S McGregor, et al.
Pageof 40